Subscribe To
Cramer's investing club: strong q4 at union pacific sets up for a solid 2022
Various factors, including taking market share from the labor-strapped trucking industry, puts Union Pacific on a strong ...
January 20, 2022, 1:52 pm
Earnings results: morgan stanley ceo sees a path to $10 trillion in assets under management as stock rally continues
Morgan Stanley shares rose for their second straight day Thursday after the bank issued a bullish view on its return on average tangible common shareh...
January 20, 2022, 1:33 pm
Earnings results: morgan stanley ceo sees a path to $10 trillion in assets under management as stock rally continues
Morgan Stanley shares rose for their second straight day Thursday after the bank issued a bullish view on its return on average tangible common shareh...
January 20, 2022, 1:33 pm
Earnings results: morgan stanley ceo sees a path to $10 trillion in assets under management as stock rally continues
Morgan Stanley shares rose for their second straight day Thursday after the bank issued a bullish view on its return on average tangible common shareh...
January 20, 2022, 1:33 pm
Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id...
January 20, 2022, 7:00 am
Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id...
January 20, 2022, 7:00 am
Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Id...
January 20, 2022, 7:00 am
Omeros submits response to fda regarding narsoplimab application in hsct-tma
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transp...
January 20, 2022, 6:54 am
Omeros submits response to fda regarding narsoplimab application in hsct-tma
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transp...
January 20, 2022, 6:54 am
Omeros submits response to fda regarding narsoplimab application in hsct-tma
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transp...
January 20, 2022, 6:54 am
Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...
January 20, 2022, 6:52 am
Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...
January 20, 2022, 6:52 am
Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...
January 20, 2022, 6:52 am
Gold to shine as investor apathy to risk falls in 2022 - sprott's grosskopf
(Kitco News) - Overconfidence and apathy towards risk dominated investor sentiment in 2021, but, according to one precious metal fund manager, that co...
January 19, 2022, 1:22 pm
Gold to shine as investor apathy to risk falls in 2022 - sprott's grosskopf
(Kitco News) - Overconfidence and apathy towards risk dominated investor sentiment in 2021, but, according to one precious metal fund manager, that co...
January 19, 2022, 1:22 pm
Gold to shine as investor apathy to risk falls in 2022 - sprott's grosskopf
(Kitco News) - Overconfidence and apathy towards risk dominated investor sentiment in 2021, but, according to one precious metal fund manager, that co...
January 19, 2022, 1:22 pm
Cvrx: the path to 7x investment returns
BaroStim Neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market, making it easier and faster to capture market...
January 7, 2022, 1:18 pm
Cvrx: the path to 7x investment returns
BaroStim Neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market, making it easier and faster to capture market...
January 7, 2022, 1:18 pm
Cvrx: the path to 7x investment returns
BaroStim Neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market, making it easier and faster to capture market...
January 7, 2022, 1:18 pm
Cgi inc.: investor day outlines the path to a narrowing valuation gap
CGI Inc.: Investor Day Outlines The path To A Narrowing Valuation Gap...
January 5, 2022, 11:47 pm